Nuvation Bio Inc. (NUVB)
NYSE: NUVB · Real-Time Price · USD
2.125
-0.005 (-0.23%)
Apr 25, 2025, 4:00 PM EDT - Market closed
Nuvation Bio Stock Forecast
Stock Price Forecast
The 5 analysts with 12-month price forecasts for Nuvation Bio stock have an average target of 8.20, with a low estimate of 5.00 and a high estimate of 10. The average target predicts an increase of 285.88% from the current stock price of 2.13.
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Nuvation Bio stock from 5 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Nov '24 | Dec '24 | Jan '25 | Feb '25 | Mar '25 | Apr '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 3 | 3 | 3 | 3 | 4 | 2 |
| Buy | 3 | 3 | 3 | 3 | 3 | 3 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 6 | 6 | 6 | 6 | 7 | 5 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| JMP Securities | JMP Securities | Buy Initiates $6 | Buy | Initiates | $6 | +182.35% | Apr 23, 2025 |
| Jones Trading | Jones Trading | Strong Buy Initiates $10 | Strong Buy | Initiates | $10 | +370.59% | Mar 12, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $11 → $10 | Strong Buy | Maintains | $11 → $10 | +370.59% | Mar 10, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $10 → $11 | Strong Buy | Maintains | $10 → $11 | +417.65% | Jan 23, 2025 |
| RBC Capital | RBC Capital | Buy Reiterates $6 → $10 | Buy | Reiterates | $6 → $10 | +370.59% | Jan 7, 2025 |
Financial Forecast
Revenue This Year
13.84M
from 7.87M
Increased by 75.73%
Revenue Next Year
74.74M
from 13.84M
Increased by 440.21%
EPS This Year
-0.67
from -2.11
EPS Next Year
-0.68
from -0.67
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 21.4M | 128.4M | 271.0M | ||
| Avg | 13.8M | 74.7M | 154.3M | ||
| Low | 5.4M | 24.5M | 49.0M |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 171.4% | 827.8% | 262.6% | ||
| Avg | 75.7% | 440.2% | 106.4% | ||
| Low | -31.5% | 77.1% | -34.4% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | -0.59 | -0.54 | -0.43 | ||
| Avg | -0.67 | -0.68 | -0.57 | ||
| Low | -0.72 | -0.87 | -0.76 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | - | - | ||
| Avg | - | - | - | ||
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.